EVOLVING ROLE OF SURGERY AFTER INDUCTION CHEMOTHERAPY AND PRIMARY SITE RADIATION IN HEAD AND NECK-CANCER

被引:9
作者
NORRIS, CM
BUSSE, PM
CLARK, JR
机构
[1] Departments of Otology and Laryngology, Harvard Medical School
[2] Division of Otolaryngology-Head and Neck Surgery, New England Deaconess Hospital
[3] Head and Neck Oncology Clinic, Dana Farber Cancer Institute, Boston, Massachusetts
来源
SEMINARS IN SURGICAL ONCOLOGY | 1993年 / 9卷 / 01期
关键词
HEAD AND NECK CANCER; CHEMOTHERAPY; RADIATION THERAPY; SURGERY; ORGAN PRESERVATION; SURVIVAL; TREATMENT MORBIDITY;
D O I
10.1002/ssu.2980090103
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chemotherapy, as preliminary treatment before surgery and/or radiation for advanced squamous cell carcinoma of the head and neck, is no longer novel. In prospective trials to date, however, multiple agent induction chemotherapy has yet to demonstrate the initial presumptive promise of improved rates of cure. As an alternate goal, there has emerged a renewed attentiveness toward limiting treatment morbidity, several strategies for which may be considered. Extirpative, often radical, surgery on the primary site of disease usually represents the most significant threat to life quality. Various ways of limiting surgical morbidity will be considered by way of introduction. The trends of head and neck cancer treatment over the decades, leading into the era of induction chemotherapy and refined radiation techniques, will be described. At the combined Dana-Farber/New England Deaconess Head and Neck Oncology Clinic, an experience with over 300 patients receiving induction chemotherapy for advanced head and neck cancer has been analyzed with an emphasis on the postulate of lessening the extent of surgery in appropriately selected patients. In a comparison between trials initiated in 1980 and 1987, improved complete response rates from 26 to 57% were documented. Survival rates were identical, but the use of planned primary site ablative surgery was decreased from 47 to 14%. While some increase in local failure has been noted in patients treated by primary site radiation alone, surgical salvage appeared to be more effective. The implication of these trends for patterns of failure and surgical salvage and data concerning the need for neck dissection in this group Of patients will be briefly summarized. Other trials addressing organ-preservation strategies will also be referenced and the dichotomy between survival-based studies and morbidity-limiting studies illustrated. Independent trends in radiation technique as a potential substitute for traditional surgical practice will be reviewed. (C) 1993 Wiley-Liss, Inc.
引用
收藏
页码:3 / 13
页数:11
相关论文
共 74 条
[1]  
Toohill RJ, Anderson T, Byhardt RW, Et al., Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report, Arch Otolaryngol Head Neck Surg, 113, pp. 758-761, (1987)
[2]  
Stell PM, Dalby JE, Strickland R, Et al., Sequential chemotherapy and radiotherapy in advanced head and neck cancer, Clin Radiol, 34, pp. 463-467, (1983)
[3]  
Schuller DE, Metch B, Stein DW, Et al., Preoperative chemotherapy in advanced resectable head and neck cancer. Final report of the Southwest Oncology Group, Laryngoscope, 98, pp. 1205-1211, (1988)
[4]  
How WK, Wolf GT, Fisher S, Et al., Larvngeal Dreservation with ynduction chemotherapy and radiothegpy in treatment for advanced laryngeal cancer: Interim survival data of VACSP #286, Proc Am Soc Clin Oncol, 8, (1989)
[5]  
Kun LE, Toohill RJ, Holoye PY, Et al., A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract, Int J Radiat Oncol Biol Phys, 12, pp. 173-178, (1986)
[6]  
Cancer, 60, pp. 301-311, (1987)
[7]  
Carugati A, Pradier R, De la Torre A, Combination chemotherapy pre‐radical treatment for head and neck squamous cell carcinoma, Proc Am Soc Clin Oncol, 7, (1988)
[8]  
Martin M, Mazeron JJ, Brun B, Et al., Neo‐adjuvant poly‐chemotherapy of head and neck cancer: Results of a randomized study, Proc Am Soc Clin Oncol, 7, (1988)
[9]  
Taylor SG, Applebaum E, Showel JL, Et al., A randomized trial of adjuvant chemotherapy in head and neck cancer, J Clin Oncol, 3, pp. 672-679, (1985)
[10]  
Spaulding MB, Kahn A, De Los Santos R, Klotch D, Et al., Adjuvant chemotherapy in advanced head and neck cancer: An update, Am J Surg, 144, pp. 432-436, (1982)